Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adverum Biotechnologies, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ADVM
Nasdaq
2830
adverum.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adverum Biotechnologies, Inc.
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vecĀ for Wet AMD
- Mar 3rd, 2025 9:01 pm
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 28th, 2025 9:00 pm
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
- Feb 25th, 2025 12:00 pm
3 US Penny Stocks With Market Caps Below $400M
- Feb 18th, 2025 5:11 pm
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Feb 5th, 2025 9:05 pm
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Nov 20th, 2024 9:05 pm
Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
- Nov 18th, 2024 1:16 pm
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
- Nov 18th, 2024 12:00 pm
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
- Nov 15th, 2024 9:05 pm
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
- Nov 4th, 2024 11:00 pm
Adverum Biotechnologies: Q3 Earnings Snapshot
- Nov 4th, 2024 10:06 pm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
- Nov 4th, 2024 9:39 pm
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
- Oct 16th, 2024 12:00 pm
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Oct 11th, 2024 4:00 pm
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
- Oct 3rd, 2024 9:17 am
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
- Sep 4th, 2024 8:05 pm
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
- Sep 3rd, 2024 1:55 pm
Adverum Biotechnologies: Q2 Earnings Snapshot
- Aug 12th, 2024 8:35 pm
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
- Aug 12th, 2024 8:05 pm
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Aug 2nd, 2024 11:00 am
Scroll